STOCK TITAN
  1. Home
  2. Sec-filings
  3. AUTL
  4. [Form 3] Autolus Therapeutics plc Initial Statement of Beneficial Ownership

Autolus Therapeutics (AUTL) director reports stock option holdings in Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Autolus Therapeutics plc director Robert Iannone filed an initial ownership report detailing his stock option holdings. The filing lists a fully vested option over 105,000 American Depositary Shares with a $2.38 exercise price expiring on June 30, 2033. It also shows an option over 80,000 ADSs at $3.48, expiring on June 28, 2034, which vests in twelve equal monthly installments commencing on July 26, 2025. A further option over 80,000 ADSs with a $2.32 exercise price expiring on June 26, 2035 is reported. These entries describe existing equity incentives and do not reflect any new market purchases or sales.

Positive

  • None.

Negative

  • None.

Insights

Form 3 shows baseline option grants, not new trading activity.

This Form 3 establishes Robert Iannone’s initial reportable position in Autolus Therapeutics equity as a director. It lists three stock option awards over American Depositary Shares with exercise prices between $2.32 and $3.48, expiring between 2033 and 2035.

One option for 105,000 ADSs is fully vested and exercisable, while another for 80,000 ADSs vests in twelve monthly installments starting July 26, 2025. Because there are no purchases, sales, or exercises reported, this filing is primarily administrative and does not, by itself, signal a change in insider sentiment.

Insider Iannone Robert
Role Director
Type Security Shares Price Value
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
Holdings After Transaction: Share Option (right to buy) — 265,000 shares (Direct)
Footnotes (2)
  1. F1. Fully vested and exercisable.
  2. F2. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does Autolus Therapeutics (AUTL) disclose in this Form 3 filing?
The Form 3 discloses director Robert Iannone’s existing stock option holdings in Autolus Therapeutics. It lists three option awards over American Depositary Shares with specified exercise prices, share amounts, vesting terms, and expiration dates, but no new purchases, sales, or exercises.

How many Autolus Therapeutics (AUTL) ADSs are covered by Robert Iannone’s options?
The filing reports options over 105,000, 80,000, and 80,000 underlying American Depositary Shares. Each option block has its own exercise price and expiration date, giving the director potential future equity exposure if the options are exercised.

What are the exercise prices of Robert Iannone’s Autolus Therapeutics (AUTL) options?
The reported options have exercise prices of $2.38, $3.48, and $2.32 per American Depositary Share. These strike prices define the cost at which he can buy ADSs if he chooses to exercise the respective options before expiration.

How do the Autolus Therapeutics (AUTL) director options vest according to the Form 3?
One option grant is described as fully vested and exercisable. Another option over 80,000 ADSs vests in twelve equal monthly installments commencing on July 26, 2025. The third grant’s vesting schedule is not further detailed in the provided excerpt.

Do the Autolus Therapeutics (AUTL) Form 3 disclosures show any insider buying or selling?
No, the Form 3 lists holdings of stock options rather than transactions. There are no open-market purchases, sales, exercises, gifts, or tax-withholding dispositions reported, so the filing functions as an initial ownership snapshot for the new director.

When do Robert Iannone’s Autolus Therapeutics (AUTL) options expire?
The reported options expire on June 30, 2033, June 28, 2034, and June 26, 2035. These dates indicate how long the director retains the right to exercise each option grant, assuming vesting and other conditions are satisfied.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Iannone Robert
(Last)(First)(Middle)
C/O AUTOLUS THERAPEUTICS PLC
THE MEDIAWORKS, 191 WOOD LN, WHITE CITY
(Street)
LONDONW12 7FP
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (right to buy) (1)06/30/2033American Depositary Shares105,000$2.38D
Share Option (right to buy) (1)06/28/2034American Depositary Shares80,000$3.48D
Share Option (right to buy) (2)06/26/2035American Depositary Shares80,000$2.32D
Explanation of Responses:
1. Fully vested and exercisable.
2. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.
/s/ Robert Iannone03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR